A Phase 3 interventional study of BHB-1893 and Placebo in Cardiomyopathy, Hypertrophic Non-Obstructive, sponsored by Braveheart Bio, Inc.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Braveheart Bio, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this trial is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy (nHCM).
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
This study's planned enrollment of 600 is above the median of 51 across 268 interventional studies indexed under Cardiomyopathies.
Browse Cardiomyopathies studies →Braveheart Bio, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Additional protocol-defined inclusion and exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive BHB-1893 twice daily.
Drug: BHB-1893
Participants will receive matching placebo twice daily.
Other: Placebo
Tablets for oral use
Tablets for oral use
Change from Baseline in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
Time frame: Baseline, Week 36
Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise (CPET)
Time frame: Baseline, Week 36
Percent Change from Baseline in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Concentration
Time frame: Baseline, Week 36
Percent Change from Baseline in High-sensitivity Cardiac Troponin I (hsc-TnI) Concentration
Time frame: Baseline, Week 36
Number of Participants with >=1 Class Improvement in New York Heart Association (NYHA) Class
Time frame: Baseline to Week 36
Change from Baseline in Left Atrial Volume Index (LAVI)
Time frame: Baseline, Week 36
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 20 phase 3 interventional studies under Cardiomyopathies, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 103. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Braveheart Bio, Inc.